Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8NE62

UPID:
CHDH_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8NE62; Q9NY17

BACKGROUND:
The mitochondrial enzyme Choline dehydrogenase, with the unique identifier Q8NE62, is integral to the conversion of choline to betaine. This conversion is essential for the synthesis of phospholipids and the regulation of homocysteine levels, implicating it in cardiovascular health and liver function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Choline dehydrogenase, mitochondrial offers a promising avenue for drug discovery. Given its central role in metabolic pathways, targeting this enzyme could lead to innovative treatments for metabolic disorders and diseases related to phospholipid metabolism.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.